GenMark Diagnostics, Inc. Sample Contracts

GENMARK DIAGNOSTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES
Indenture • June 14th, 2016 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York

INDENTURE, dated as of [●], 20[●], among GENMARK DIAGNOSTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):

AutoNDA by SimpleDocs
GENMARK DIAGNOSTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES
GenMark Diagnostics, Inc. • November 20th, 2018 • Surgical & medical instruments & apparatus • New York

INDENTURE, dated as of [—], 20[—], among GENMARK DIAGNOSTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):

UNDERWRITING AGREEMENT GENMARK DIAGNOSTICS, INC. 6,382,978 Shares of Common Stock Underwriting Agreement
Underwriting Agreement • June 14th, 2017 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York
—] Shares1 GenMark Diagnostics, Inc. Common Stock, $0.0001 par value per share PURCHASE AGREEMENT
Purchase Agreement • May 13th, 2010 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York

GenMark Diagnostics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [—] shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of [—] authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to [—] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement are herein collectively called the “Securities.”

] Shares GenMark Diagnostics, Inc. Common Stock, $0.0001 par value per share UNDERWRITING AGREEMENT
Underwriting Agreement • June 8th, 2011 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York

GenMark Diagnostics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ] shares (the “Initial Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Company has also granted to the several Underwriters an option to purchase up to [ ] additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Initial Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”

GENMARK DIAGNOSTICS, INC. STOCK OPTION AGREEMENT
Stock Option Agreement • April 20th, 2010 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

Genmark Diagnostics, Inc. (the “Company”) has granted to the Participant named in the Notice of Grant of Stock Option (the “Grant Notice”) to which this Stock Option Agreement (the “Option Agreement”) is attached an option (the “Option”) to purchase certain shares of Stock upon the terms and conditions set forth in the Grant Notice and this Option Agreement. The Option has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Genmark Diagnostics, Inc. 2010 Equity Incentive Plan (the “Plan”), as amended to the Date of Grant, the provisions of which are incorporated herein by reference. By signing the Grant Notice, the Participant: (a) acknowledges receipt of, and represents that the Participant has read and is familiar with, the Grant Notice, this Option Agreement, the Plan and a prospectus for the Plan prepared in connection with the registration with the Securities and Exchange Commission of shares issuable pursuant to the Option (the “Plan P

GENMARK DIAGNOSTICS, INC. RESTRICTED STOCK UNITS AGREEMENT (For U.S. Participants)
Restricted Stock Units Agreement • June 2nd, 2020 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

GenMark Diagnostics, Inc. has granted to the Participant named in the Notice of Grant of Restricted Stock Units (the “Grant Notice”) to which this Restricted Stock Units Agreement (the “Agreement”) is attached an Award consisting of Restricted Stock Units (each a “Unit”) subject to the terms and conditions set forth in the Grant Notice and this Agreement. The Award has been granted pursuant to and shall in all respects be subject to the terms and conditions of the GenMark Diagnostics, Inc. 2020 Equity Incentive Plan (the “Plan”), as amended to the Date of Grant, the provisions of which are incorporated herein by reference. By signing the Grant Notice, the Participant: (a) acknowledges receipt of and represents that the Participant has read and is familiar with the Grant Notice, this Agreement, the Plan and a prospectus for the Plan prepared in connection with the registration with the Securities and Exchange Commission of the shares issuable pursuant to the Award (the “Plan Prospectus”

GENMARK DIAGNOSTICS, INC. EQUITY DISTRIBUTION AGREEMENT
Equity Distribution Agreement • August 5th, 2019 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York

GenMark Diagnostics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Canaccord Genuity LLC (“Canaccord”), as follows:

GENMARK DIAGNOSTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES
GenMark Diagnostics, Inc. • November 20th, 2018 • Surgical & medical instruments & apparatus • New York

Page ARTICLE I DEFINITIONS Section 1.01 Definitions of Terms 2 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2.03 Denominations: Provisions for Payment 7 Section 2.04 Execution and Authentications 8 Section 2.05 Registration of Transfer and Exchange 8 Section 2.06 Temporary Securities 10 Section 2.07 Mutilated, Destroyed, Lost or Stolen Securities 10 Section 2.08 Cancellation 10 Section 2.09 Benefits of Indenture 11 Section 2.10 Authenticating Agent 11 Section 2.11 Global Securities 11 ARTICLE III REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS 13 Section 3.01 Redemption 13 Section 3.02 Notice of Redemption 13 Section 3.03 Payment Upon Redemption 13 Section 3.04 Sinking Fund 14 Section 3.05 Satisfaction of Sinking Fund Payments with Securities 14 Section 3.06 Redemption of Securities for Sinking Fund 14 ARTICLE IV COVEN

GENMARK DIAGNOSTICS, INC. 7,253,886 Shares of Common Stock Underwriting Agreement
Letter Agreement • May 7th, 2020 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York

GenMark Diagnostics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 7,253,886 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,088,082 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.

LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • April 30th, 2019 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York

THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of February 1, 2019 (the “Effective Date”) among Solar Capital Ltd., a Maryland corporation (“Solar”), as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and the lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Solar in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and GenMark Diagnostics, Inc., a Delaware corporation (“GenMark”), Clinical Micro Sensors, Inc., a Delaware corporation (“CMS”), and Osmetech Inc., a Delaware corporation (“Osmetech”, and together with GenMark and CMS, individually and collectively, jointly and severally, “Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:

INDEMNIFICATION AGREEMENT
Indemnification Agreement • March 19th, 2010 • GenMark Diagnostics, Inc. • Delaware

This Indemnificaton Agreement, dated as of , 2010, is made by and between GenMark Diagnostics, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”).

AGREEMENT AND PLAN OF MERGER among: ROCHE HOLDINGS, INC., a Delaware corporation, GERONIMO ACQUISITION CORP., a Delaware corporation, and GENMARK DIAGNOSTICS, INC., a Delaware corporation Dated as of March 12, 2021
Agreement and Plan of Merger • March 15th, 2021 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • Delaware

This AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of March 12, 2021 (the “Agreement Date”) by and among Roche Holdings, Inc., a Delaware corporation (“Parent”), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”), and GenMark Diagnostics, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

40,000,000 CREDIT FACILITY LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • May 5th, 2015 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • New York

THIS LOAN AND SECURITY AGREEMENT, dated as of January 12, 2015 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), is among General Electric Capital Corporation (“GECC”), in its capacity as administrative and collateral agent for Lenders (together with its successors and assigns in such capacity, “Agent”), the financial institutions who are or hereafter become parties to this Agreement as lenders (together with GECC, collectively the “Lenders”, and each individually, a “Lender”), GenMark Diagnostics, Inc., a Delaware corporation (“Borrower”), and the other Persons (as defined below), if any, who are or hereafter become parties to this Agreement as guarantors (each a “Guarantor” and collectively, the “Guarantors”, and together with Borrower, each a “Loan Party” and collectively, “Loan Parties”).

EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • May 13th, 2011 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

This Executive Employment Agreement (“Agreement”) is entered into as of March 1, 2010 (“Effective Date”), by Osmetech Technology, Inc. and subsidiaries (“Company”) and Jeffrey Hawkins (“Executive”). Company and Executive are each a “Party” to this Agreement and are sometimes collectively referred to as “Parties.” This Agreement supersedes any previous written or verbal agreements.

NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY CLINICAL MICRO SENSORS DBA OSMETECH MOLECULAR DIAGNOSTICS JHU Ref: 9328
Non-Exclusive License Agreement • May 25th, 2010 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • Maryland

This Non-exclusive License Agreement (hereinafter referred to as the “Agreement”) is by and between The Johns Hopkins University (hereinafter referred to as “JHU”), a corporation of the State of Maryland, having a principal place of business at 3400 N. Charles Street, Baltimore, Maryland 21218-2695, and Clinical Micro Sensors (hereinafter referred to as “Company”), Doing Business As Osmetech Molecular Diagnostics, a corporation incorporated in the State of California, located at 757 South Raymond Avenue., Pasadena, CA 91105.

Contract
GenMark Diagnostics, Inc. • May 25th, 2010 • Surgical & medical instruments & apparatus

This draft is dated October 18, 2007, and is solely for purposes of negotiation. No contract shall exist until a final, written agreement is signed by MARSHFIELD CLINIC and an authorized representative of Licensee. This draft shall expire on November 10, 2007.

LICENSE AGREEMENT: INTRONS AND EXONS OF THE CYSTIC FIBROSIS GENE AND MUTATIONS AT VARIOUS POSITIONS OF THE GENE
License Agreement • May 25th, 2010 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • Ontario

This is an Agreement, effective as of the 15th day of March, 2006 (the “Effective Date”), entered into by Clinical Micro Sensors, Inc., DBA Osmetech Molecular Diagnostics, a corporation incorporated in California, located at 757 S. Raymond Avenue, Pasadena, CA 91105 (including all affiliates licensed hereunder, hereinafter collectively referred to as “LICENSEE”), and HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP, a partnership organized and subsisting under the laws of the Province of Ontario, Canada (“RDLP”). LICENSEE and RDLP agree as follows:

AMENDED AND RESTATED CHEMICALLY MODIFIED ENZYMES KIT PATENT LICENSE AGREEMENT
Chemically Modified • May 21st, 2010 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus

This License Agreement (“Agreement”) is made by and between Roche Molecular Systems, Inc., a Delaware corporation having an office at 4300 Hacienda Drive, Pleasanton, California 94588, USA and F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland (hereinafter jointly referred to as “ROCHE”) and Osmetech Molecular Diagnostics, 757 S. Raymond Avenue, Pasadena, CA 91105 (hereinafter referred to as “LCE”) hereafter collectively referred to as “The Parties”.

OSMETECH TECHNOLOGY, INC. CLINICAL MICRO SENSORS, INC. GENMARK DIAGNOSTICS, INC. LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • March 21st, 2012 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California
THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • March 2nd, 2020 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus

THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of February 27, 2020 (the “Amendment Effective Date”), is made among GenMark Diagnostics, Inc., a Delaware corporation (“GenMark”), Clinical Micro Sensors, Inc., a Delaware corporation (“CMS”), and Osmetech Inc., a Delaware corporation (“Osmetech”, and together with GenMark and CMS, individually and collectively, jointly and severally, “Borrower”), Solar Capital Ltd., a Maryland corporation (“Solar”), in its capacity as collateral agent (in such capacity, “Collateral Agent”) and the Lenders listed on Schedule 1.1 of the Loan and Security Agreement (as defined below) or otherwise a party hereto from time to time including Solar in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”).

LICENSE AGREEMENT MICHIGAN FILE 492p2 TECHNOLOGY DIAGNOSTIC PRODUCT DISTRIBUTION LICENSE
License Agreement • May 21st, 2010 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • Michigan

This License Agreement, effective as of the 15th day of March, 2006 (the “Effective Date”), entered into by Clinical Micro Sensors, DBA Osmetech Molecular Diagnostics, a corporation incorporated in the State of California located at 757 South Raymond Avenue, Pasadena, California 91105, USA (“LICENSEE”), the Regents of the University of Michigan, a constitutional corporation of the State of Michigan (“MICHIGAN”), and HSC Research and Development Limited Partnership, a partnership organized and subsisting under the laws of the Province of Ontario, Canada (“RDLP”). LICENSEE, MICHIGAN and RDLP agree as follows:

AutoNDA by SimpleDocs
LICENSE AGREEMENT
License Agreement • May 21st, 2010 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

This AGREEMENT is effective as of the 8th day of February 1995, between California Institute of Technology, 1201 East California Boulevard, Pasadena, California 91125 (“CALTECH”) and Clinical Micro Sensors, Inc., 428 South Sierra Bonita Avenue, Pasadena, CA 91106 (“CMS”), a corporation of the State of California:

THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • March 21st, 2012 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus

This Third Amendment to Loan and Security Agreement (“Amendment”), is entered into as of March 9, 2011, by and between SQUARE 1 BANK (“Bank”) and OSMETECH TECHNOLOGY, INC., CLINICAL MICRO SENSORS, INC. and GENMARK DIAGNOSTICS, INC., (each individually, a “Borrower”, and collectively known as “Borrower”).

SECOND AMENDMENT TO LICENSE AGREEMENT
License Agreement • April 18th, 2013 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

This Second Amendment to the License Agreement is effective as of the 20th day of June, 2000 (the “Second Amendment Effective Date”) between California Institute of Technology, 1200 East California Boulevard, Pasadena, California 91125 (“CALTECH”) and Clinical Micro Sensors, Inc. (“LICENSEE”):

NON-EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN OSMETECH AND THE UNIVERSITY OF WASHINGTON UW REFERENCE: 7063-18921A UW TECHTRANSFER, INVENTION LICENSING NEGOTIATED BY CHRISTINE HAN, PH.D., M.P.H.
Patent License Agreement • May 21st, 2010 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • Washington

This Agreement (“Agreement”) is dated and effective as of the date of last signature (the “Effective Date”), and is made by and between the University of Washington, a public institution of higher education and an agency of the state of Washington (the “University”), and Osmetech Molecular Diagnostics, an entity consisting solely of Clinical Micro Sensors, Inc. and Osmetech, Inc., both Delaware Corporations (the “Company”), (individually a “Party” or collectively the “Parties”).

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • March 21st, 2012 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus

This First Amendment to Loan and Security Agreement (“Amendment”), is entered into as of August 17, 2010, by and between Square 1 Bank (“Bank”) and Osmetech Technology, Inc. (“Osmetech”), Clinical Micro Sensors, Inc. (“CMSI”), and Genmark Diagnostics, Inc. (“Genmark”), (each individually and collectively known as (“Borrower”).

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • March 21st, 2012 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus

This Second Amendment to Loan and Security Agreement (“Amendment”), is entered into as of September 29, 2010, by and between Square 1 Bank (“Bank”) and Osmetech Technology, Inc. (“Osmetech”), Clinical Micro Sensors, Inc. (“CMSI”), and Genmark Diagnostics, Inc. (“Genmark”), (each individually and collectively known as (“Borrower”).

REAGENT RENTAL AGREEMENT
Reagent Rental Agreement • March 22nd, 2013 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

This Reagent Rental Agreement (this “Agreement”) is made and entered as of the Effective Date (as such term is defined below), by and between Clinical Micro Sensors, Inc., a Delaware corporation doing business as GenMark Diagnostics (“GenMark”), and the customer identified in the “Customer Information” table immediately below (the “Customer”). As used in this Agreement, “Effective Date” means the latest date set forth on the signature blocks of this Agreement. This Agreement replaces and supersedes, as of the Effective date, the prior Reagent Rental Agreement dated May 1, 2012.

XT-8 INSTRUMENT SUPPLY AGREEMENT
Supply Agreement • March 22nd, 2013 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

Leica Biosystems Melbourne Pty Ltd (ABN 72 008 582 401) a company incorporated under the laws of Australia, having its registered office at 495 Blackburn Road, Mount Waverley, Victoria, 3149 Australia, (hereinafter referred to as “Leica”)

SETTLEMENT AND RELEASE AGREEMENT AND FIRST AMENDMENT TO LEASE [THE CAMPUS CARLSBAD]
Settlement and Release Agreement • March 14th, 2013 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus

THIS SETTLEMENT AND RELEASE AGREEMENT AND FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of the 1st day of July, 2010, by and between THE CAMPUS CARLSBAD, LLC, a Delaware limited liability company (“Landlord”) and GENMARK DIAGNOSTICS, INC., a Delaware corporation (“Tenant”). Landlord and Tenant are sometimes hereinafter collectively referred to as the “Parties” or, individually, a “Party.”

CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE
Confidential Separation Agreement and General Release • May 4th, 2020 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

This Separation Agreement and General Release (“Agreement”), dated as of April 25, 2020, is made between Hany Massarany, on behalf of himself, his agents, assignees, heirs, executors, administrators, beneficiaries, trustees and legal representatives (“Employee”), and GenMark Diagnostics, Inc., by and for itself, its subsidiaries, successors and assigns (collectively, the “Company”). Employee and Company are each a “Party” and are collectively sometimes referred to as “Parties” to this Agreement.

GENMARK DIAGNOSTICS, INC. AMENDMENT OF RESTRICTED STOCK UNIT AND/OR STOCK OPTION AGREEMENT(S)
Stock Option Agreement • June 2nd, 2020 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

THIS AMENDMENT OF RESTRICTED STOCK UNIT AND/OR STOCK OPTION AGREEMENT(S) (this “Amendment”) is made by and between GenMark Diagnostics, Inc., a Delaware corporation (the “Company”), and __________________ (the “Participant”).

SINGLE TENANT INDUSTRIAL TRIPLE NET LEASE
Single Tenant Industrial Triple Net Lease • October 28th, 2020 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus

This Single Tenant Industrial Triple Net Lease (this “Lease”) is made and entered into as of July 2, 2020 (the “Effective Date”), by and between Icon Owner Pool 1 West/Southwest, LLC, a Delaware limited liability company (“Landlord”) and GenMark Diagnostics, Inc., a Delaware corporation (“Tenant”). The following exhibits and attachments are incorporated into and made a part of this Lease: Exhibit A (Outline and Location of Premises), Exhibit B (Work Letter), Exhibit C (Prohibited Use), Exhibit D (Rules and Regulations), Exhibit E (Confirmation Letter, if required), Exhibit F (Requirements for Improvements or Alterations by Tenant), Exhibit G (Hazardous Materials Survey Form), Exhibit H (Move Out Conditions), Exhibit I (Minimum Service Contract Requirements), Exhibit J (Additional Provisions), and Exhibit K (Judicial Reference).

EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • May 13th, 2011 • GenMark Diagnostics, Inc. • Surgical & medical instruments & apparatus • California

This Executive Employment Agreement (“Agreement”), dated as of April 5, 2011 (the “Execution Date”), is made by and between GenMark Diagnostics, Inc. (“Company”) and Hany Massarany (“Executive”).

Time is Money Join Law Insider Premium to draft better contracts faster.